Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Interim Chief Legal Officer | September 18, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 8,500 |
Ending reported balance
After 2026-09-18 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-18 · Exercise / conversion · Acquired 4,503 · Balance 15,842 Row 2 · 2026-09-18 · Sale · Disposed 4,503 · Balance 11,339 Row 3 · 2026-09-18 · Sale · Disposed 2,525 · Balance 8,814 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2026-09-18 · Sale · Disposed 314 · Balance 8,500 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.70 · Expires 2027-03-03 | Direct | 0 |
Reported balance
After 2026-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-18 · Exercise / conversion · Disposed 4,503 · Balance 0 F2: Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionStock Options (right to buy) · Derivative | 4,503 | $34.70 Strike: $34.70 | $156,254.10 |
DisclosureSEC source: 0001193125-26-398105 · ownership.xml · derivative · entry 5 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,503 shares Expires 2027-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 314 | $38.70 | $12,152.99 |
DisclosureSEC source: 0001193125-26-398105 · ownership.xml · nonDerivative · entry 4 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,525 | $39.15 | $98,841.13 |
DisclosureSEC source: 0001193125-26-398105 · ownership.xml · nonDerivative · entry 3 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,814 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,503 | $38.69 | $174,221.07 |
DisclosureSEC source: 0001193125-26-398105 · ownership.xml · nonDerivative · entry 2 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,339 Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,503 | $34.70 | $156,254.10 |
DisclosureSEC source: 0001193125-26-398105 · ownership.xml · nonDerivative · entry 1 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098501 · ownership.xml · derivative · entry 3 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,740 Underlying: Ordinary Shares · 3,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 3,580 vested on March 5, 2026, and 3,580 vesting on each of March 5, 2027, March 7, 2028 and March 5, 2029. F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 3,580 vested on March 5, 2026, and 3,580 vesting on each of March 5, 2027, March 7, 2028 and March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,127 | $31.67 | $35,690.29 |
DisclosureSEC source: 0001193125-26-098501 · ownership.xml · nonDerivative · entry 2 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,914 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098501 · ownership.xml · nonDerivative · entry 1 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 11,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · derivative · entry 7 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,280 Underlying: Ordinary Shares · 11,280 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · derivative · entry 6 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,534 Underlying: Ordinary Shares · 3,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · derivative · entry 5 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,186 | $32.46 | $38,502.90 |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · nonDerivative · entry 4 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,461 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · nonDerivative · entry 3 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,489 | $32.46 | $48,339.64 |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · nonDerivative · entry 2 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,181 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,744 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096477 · ownership.xml · nonDerivative · entry 1 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093930 · ownership.xml · derivative · entry 3 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,461 Underlying: Ordinary Shares · 3,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 3,461 vesting on March 3, 2027. F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 3,461 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,274 | $32.36 | $41,226.51 |
DisclosureSEC source: 0001193125-26-093930 · ownership.xml · nonDerivative · entry 2 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,926 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093930 · ownership.xml · nonDerivative · entry 1 Savage Brian · CIK 0002112339 · Interim Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.